![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Absence of Significant Drug-Drug Interactions Between Next Generation Direct Acting Antivirals ABT-493 and ABT-530 and Methadone or Buprenorphine/Naloxone in Subjects on Opioid Maintenance Therapy ..... "no dose adjustments required"
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco, CA
Matthew P. Kosloski, Sandeep Dutta, Weihan Zhao, Armen Asatryan, Jens Kort, Wei Liu AbbVie Inc., North Chicago, Illinois, United States
![AASLD1.gif](../images/111815/111815-4/AASLD1.gif)
![AASLD2.gif](../images/111815/111815-4/AASLD2.gif)
![AASLD3.gif](../images/111815/111815-4/AASLD3.gif)
![AASLD4.gif](../images/111815/111815-4/AASLD4.gif)
![AASLD5.gif](../images/111815/111815-4/AASLD5.gif)
![AASLD6.gif](../images/111815/111815-4/AASLD6.gif)
![AASLD7.gif](../images/111815/111815-4/AASLD7.gif)
![AASLD8.gif](../images/111815/111815-4/AASLD8.gif)
![AASLD9.gif](../images/111815/111815-4/AASLD9.gif)
![AASLD10.gif](../images/111815/111815-4/AASLD10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|